Bayer’s Structural Pivot Fuels Analyst Upgrades, But Overbought Signals and a Key Court Date Loom
Published on 07/07/2026 at 06:31 | Redaktion boerse-global.de
The creation of a dedicated US glyphosate unit has shifted the risk calculus for Bayer, prompting a fresh wave of analyst upgrades that have pushed the stock to levels not seen in over a year. The German chemical and pharma giant carved its American glyphosate operations into a standalone subsidiary, Ruveon LLC, based in St. Louis, earlier this month, retaining full ownership while ring-fencing pricing, production, and logistics for the controversial herbicide. The move has been read by Wall Street as a tangible step toward capping the legal overhang from Roundup lawsuits, and the rating agencies have responded in kind.
Goldman Sachs lifted its price target to €62.50 from €55, keeping a Buy rating, as analyst James Quigley lowered his cost-of-capital assumptions on the back of reduced legal risk. Deutsche Bank followed suit by upgrading the stock from Hold to Buy with a €60 target, while DZ Bank raised its fair-value estimate to €54. The upgrades have added fuel to a rally that already looked frothy: Bayer shares closed Monday at €50.98, a 43.28% gain over the past 30 days and a 34.07% advance since the start of the year. On a 12-month basis the stock has nearly doubled, climbing 95.66%.
Yet the speed of the ascent has pushed technical indicators into overbought territory. The 14-day relative strength index sits at 75.2, and the stock’s 30% premium over its 50-day moving average of €39.11 underscores how far and fast the move has been. With shares now trading just 5.35% below a 52-week high of €53.86 hit on July 3, many market participants are warning that fresh catalysts will be needed to sustain further gains.
Should investors sell immediately? Or is it worth buying Bayer?
The most immediate catalyst is a court hearing scheduled for July 9, when a US judge is expected to deliver final approval of the $7.25 billion Roundup class-action settlement. A positive ruling would dramatically reduce Bayer’s future litigation exposure. Shortly after, on the last week of July, second-quarter results will test whether the operational turnaround is keeping pace with the market’s re-rating narrative. According to Quigley, the earnings report is unlikely to hold major surprises; instead, he sees investor attention shifting toward a possible broader breakup of the conglomerate, which could further close the valuation discount that has dogged Bayer for years.
Despite the recent analyst upgrades, opinion on the Street remains divided. A majority of ratings still carry a Hold recommendation, with only a minority fully embracing the restructuring story. The Deutsche Bank upgrade and the Goldman Sachs target hike represent a notable shift, but the technical overhang and the binary nature of the upcoming court decision suggest that the next leg of the rally will require both legal clarity and sustained operational improvement.
Ad
Bayer Stock: New Analysis - 7 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
